Roche and Novartis AG have been dealt another blow in their long-running European battle to stop Avastin (bevacizumab) being used for wet age-related macular degeneration (wAMD) in place of the more expensive Lucentis (ranibizumab) after the High Court said 12 clinical commissioning groups in northeast England could continue to offer Avastin to wAMD patients in order to save money, even though it is not approved for that use.
Under a policy adopted in 2017, the CCGs offered Roche's Avastin to certain patients with wAMD as the "preferred treatment...







